Even though conventional routine blood tests and liver function indicators (e.g., AST, ALT, GGT, TBIL, and DBIL) are useful in the diagnosis and monitoring of BA, these biochemical markers have limited diagnostic efficacy in identifying progressive liver fibrosis (F ≥ 3) and are unable to provide effective clinical assistance for accurate judgment in patients with BA (9). The gene discussed is GPT; the disease is breast angiosarcoma.